SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer Breast 2 Mins Read41 The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read256 … [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium…
NATALEE Trial ESMO 2023: Guideline Changes? Breast 2 Mins Read12 By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into…
